Much progress has been made in breast cancer treatment: in addition to chemotherapy and endocrine therapy, the integration of targeted molecular therapies, in particular anti-HER 2 drugs, has revolutionized the management of Her2 positive breast cancer cases [2]. The gene discussed is ERBB2; the disease is breast carcinoma.